ML Bio Solutions
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, ML Bio Solutions sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
ML Bio Solutions: 4 sponsored US clinical trials, none currently recruiting.
ML Bio Solutions sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I), with 1 trials.
Upper-quartile sponsor footprint
ML Bio Solutions sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9
NCT07678775
Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)
NCT05775848
Study of BBP-418 in Patients With LGMD2I
NCT04800874
Biomarker Development in LGMD2i
NCT04202627
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 2 |
Therapeutic Areas
How the ML Bio Solutions archive is shaped
4 indexed studies, none listed as recruiting (0% open); 1 completed (25%).
Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
ML Bio Solutions: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
ML Bio Solutions sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this ML Bio Solutions page
4 registered trials is a research-attention snapshot, not an endorsement of ML Bio Solutions or any single study.
- None of ML Bio Solutions's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) is the condition ML Bio Solutions studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. ML Bio Solutions pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.